Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19.

Ishay, Yuval; Potruch, Assaf; Weksler-Zangen, Sarah; Shabat, Yehudit; Ilan, Yaron

Ishay, Yuval; Potruch, Assaf; Weksler-Zangen, Sarah; Shabat, Yehudit; Ilan, Yaron.

Afiliação

Ishay Y; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Potruch A; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Weksler-Zangen S; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Shabat Y; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Ilan Y; Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.

Drug Dev Res ; 83(3): 615-621, 2022 05.

Article em En | MEDLINE | ID: mdl-34596893

Assuntos

COVID-19; Colostro; Administração Oral; Animais; Antígenos Virais; Antivirais/farmacologia; Antivirais/uso terapêutico; Bovinos; Feminino; Humanos; Fatores Imunológicos; Interferon gama; Masculino; Camundongos; Gravidez; Linfócitos T

Palavras-chave

COVID-19; T cell immunity; antiviral treatment; prevention

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 4_TD Base de dados: MEDLINE Assunto principal: Colostro / COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male / Pregnancy Idioma: En Revista: Drug Dev Res Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google